Csl Behring

This study is testing the safety of an experimental drug called anumigilimab in adults with sickle cell disease. Over 64 weeks, researchers will monitor side effects while participants receive injections of the drug or a placebo. The goal is to see if the treatment is safe and if…

This study is checking if it's safe for people with hereditary angioedema (HAE) to switch from their current preventive treatment to a new monthly injection called garadacimab. It will involve about 30 people aged 12 and older who are already on a stable HAE prevention regimen. P…

This study is testing an investigational drug called CSL300 (clazakizumab) to see if it can lower the risk of heart attacks and death in people with end-stage kidney disease who are on dialysis. The trial will enroll over 2,300 adults who have both kidney failure and either heart…

This program allows children aged 2 to 11 with hereditary angioedema (HAE) to continue receiving a preventive drug called garadacimab after they finish a previous clinical trial. It is for kids who did well on the drug, had few or no swelling attacks, and had no major side effect…

This study aims to understand how a medication called IgPro20 works in the body and how safe it is for adults with primary immunodeficiency (PID) who have never received immune globulin (IG) treatment. The medicine is given as an injection under the skin. Researchers will measure…

This study is testing a one-time gene therapy called CSL222 in adults with severe hemophilia B who have pre-existing antibodies that normally block this type of treatment. The main goal is to see if the therapy safely reduces bleeding episodes and the need for regular clotting fa…

This study is testing a new version of a standard clotting factor medicine (called rVIII-SingleChain) specifically in Chinese patients with severe hemophilia A. The main goals are to see how the drug moves through the body, how well it prevents and treats bleeding episodes, and t…

This study aims to find the best dose of a medicine called Privigen (IVIG) to control symptoms and prevent relapse in children aged 2-17 with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disorder. Researchers will compare two different dose levels to see…

This study is testing a single-dose gene therapy called CSL222 in teenage boys with severe hemophilia B. The goal is to see if this one-time treatment can help their bodies produce their own clotting factor, reducing or eliminating the need for regular infusions to prevent bleeds…

This study is testing an investigational drug called vamifeport for adults with hereditary hemochromatosis, a condition where the body absorbs too much iron. The main goal is to see if vamifeport can safely reduce the amount of iron stored in the liver, which is measured by a spe…

This study is testing an experimental medicine (BE1116) designed to help blood clot better during and after complex heart surgery that uses a heart-lung bypass machine. It will compare this medicine to the standard treatment, fresh frozen plasma, in 200 adults who start bleeding …

This study is testing a new inhaled antibody treatment called CSL787 for adults with non-cystic fibrosis bronchiectasis, a chronic lung condition. The main goal is to see if the treatment can delay or reduce the frequency of sudden worsening of symptoms, known as exacerbations, a…

This study follows 500 people with hemophilia B who have received HEMGENIX gene therapy to understand its long-term effectiveness and safety. Researchers will track how many bleeding episodes patients experience and compare results to those receiving standard preventive treatment…

This study follows 200 patients with hereditary angioedema (HAE) for four years after they start a medication called garadacimab. The main goal is to see how well the drug reduces painful swelling attacks and improves patients' daily lives outside of controlled clinical trials. R…

This study is testing whether an intravenous medication called CSL889 can help shorten painful vaso-occlusive crises in people with sickle cell disease. Researchers will give the drug or a placebo to 70 adults and adolescents who come to the hospital with these sudden, severe pai…